Nom du produit:(2S,4R)-1-[(tert-butoxy)carbonyl]-4-fluoropyrrolidine-2-carboxylic acid
IUPAC Name:(2S,4R)-1-[(tert-butoxy)carbonyl]-4-fluoropyrrolidine-2-carboxylic acid
- CAS：203866-14-2
- Formule moléculaire：C10H16FNO4
- Pureté：97%
- Numéro de catalogue：CM103652
- Poids moléculaire：233.24
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:203866-14-2
- Formule moléculaire:C10H16FNO4
- Point de fusion:-
- Code SMILES:CC(C)(C)OC(=O)N1C[C@H](F)C[C@H]1C(O)=O
- Densité:
- Numéro de catalogue:CM103652
- Poids moléculaire:233.24
- Point d'ébullition:
- N° Mdl:MFCD06796085
- Stockage:
Category Infos
- Amino Acids and Peptides
- Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.
- amino acids wholesale
- if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!
- Pyrrolidines
- Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.
Column Infos
- Voydeya
- Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.
Recherche 
+86 21 5895 0110 
